5090792026-08-145090792026-08-142026-08-14iso4217:INRxbrli:pure509079Gufic Biosciences LimitedGUFICBIONOTLISTEDINE742B01025NewAcquisition of “to be incorporated companies”true2026-08-1418:10:002026-08-14Note 1 : The “Date of Incorporation” field is mandatory for validation of the XBRL filing. Accordingly, 14.08.2026 has been entered solely for the purpose of completing the XBRL validation. It is clarified that the proposed subsidiary has not yet been incorporated and is expected to be incorporated within twelve months from the date hereof, subject to completion of all applicable statutory and regulatory formalities. <BR> <BR> Note 2 : The amount specified under “Cash Consideration” represents the maximum investment limit approved by the Board. The Board has approved an investment of up to USD 250,000, or its equivalent amount in Philippine Peso, approximately equivalent to Rs.2.4 crores based on the prevailing exchange rate as on the date hereof. Since the relevant XBRL field accepts only a numeric value, the maximum approved investment limit has been reported therein. The actual amount of investment will be determined at the time of incorporation of the proposed subsidiary and will be disclosed accordingly.Gufic Biosciences LimitedListed Entity (self)Gufic Philippines IncPharmaceuticalsThe proposed subsidiary will undertake marketing, sale, distribution and other allied activities in relation to the Company’s pharmaceutical products in the Philippines and facilitate the expansion of the Company’s business and presence in the Philippines, including holding and managing Intellectual Property Rights in the Philippines.YesThe proposed incorporation and investment are subject to applicable statutory and regulatory requirements, including incorporation/registration with the Securities and Exchange Commission (SEC), Philippines, applicable pharmaceutical regulatory approvals/licences and registrations, as may be applicable, and compliance with applicable foreign exchange / overseas investment regulations in India.Cash2400000Investment of up to USD 250,000 (United States Dollars Two Hundred Fifty Thousand only), or its equivalent amount in Philippine Peso.Cost/PriceCash consideration by way of subscription to the equity share capital of the proposed subsidiary, for an amount of up to USD 250,000 (United States Dollars Two Hundred Fifty Thousand only), or its equivalent amount in Philippine Peso.0.99992026-08-14PhilippinesNil, except as stated above and in the notes